Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction

Journal of the American College of Cardiology

Volumn 32, Issue 1, 1998, Pages 35-41

  Anderson, Jeffrey L ^a,b   Carlquist, John F ^a   Muhlestein, Joseph B ^a   Horne, Benjamin D ^a   Elmer, Sidney P ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN G;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS; FEMALE; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VIRUS INFECTION;

ADULT; AGED; C-REACTIVE PROTEIN; CHLAMYDOPHILA PNEUMONIAE; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CYTOMEGALOVIRUS; FEMALE; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0032127743     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00203-4     Document Type: Article

References (43)

1. National Heart, Lung, and Blood Institute Fact Book. Fiscal Year 1995. US Department of Health and Human Services Monograph. March, 1996:30-52.
2. Farmer J.A., Gotto A.M. Jr. Dyslipidemia and other risk factors for coronary artery disease. Braunwald E. Heart Disease A Textbook of Cardiovascular Medicine . 5th ed. 1997;1126-1160 WB Saunders, Philadelphia.
3. Robinson K., Mayer E.L., Miller D.P., et al. Hyperhomocysteinemia and low pyridoxal phospate common and independent reversible risk factors for coronary artery disease . Circulation. 92:1995;2825-2830.
4. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 57:1995;791-804.
5. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
6. Shah P.K., Falk E., Badimon J.J., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques potential role of matrix-degrading metalloproteinases and implications for plaque rupture . Circulation. 92:1995;1565-1569.
7. Maseri A. Inflammation, atherosclerosis, and ischemic events - exploring the hidden side of the moon. N Engl J Med. 336:1997;1014-1016.
8. Berk B.C., Weintraub W.S., Alexander R.W. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 65:1990;168-172.
9. de Beer F.C., Hind C.R., Fox K.M., Allan R.M., Maseri A., Pepys M.B. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction. Br Heart J. 47:1982;239-243.
10. Pietila K., Marmoinen A., Hermens W., Simoons M.L., Van de Werf F., Verstraete M. Serum C-reactive protein concentration in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J. 14:1993;915-919.
11. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 331:1994;417-424.
12. Thompson S.G., Kienast J., Pyke S.D.M., Haverkate F., van de Loo J.C.W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641.
13. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
14. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 144:1996;537-547.
15. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1996;973-979.
16. Saikku P., Leinonen M., Mattila K., et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 2:1988;983-985.
17. Saikku P., Leinonen M., Tenkanen L., et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 116:1992;273-278.
18. Thom D.H., Grayston J.T., Siscovick D.S., Wang L.-P., Weiss N.S., Daling J.R. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 268:1992;68-72.
19. Aldous M.B., Grayston J.T., Wang S.P., Foy H.M. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. J Infect Dis. 166:1992;646-649.
20. Kuo C.C., Shor A., Campbell L.A., Fukushi H., Patton D.L., Grayston J.T. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 167:1993;841-849.
21. Muhlestein J.B., Hammond E.H., Carlquist J.F., et al. Increased incidence of Chlamydia species within the coronary arteries of patients with severe atherosclerosis versus other forms of cardiovascular disease. J Am Coll Cardiol. 27:1995;1555-1561.
22. Ramirez J.A. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med. 125:1996;979-982.
23. Grayston J.T. Chlamydia in atherosclerosis. Circulation. 87:1993;1408-1409.
24. Melnick J.L., Adam E., Debakey M.E. Possible role of cytomegalovirus in atherogenesis. JAMA. 263:1990;2204-2207.
25. Dummer S., Lee A., Breinig M.K., Kormos R., Ho M., Griffith B. Investigation of cytomegalovirus infection as a risk factor for coronary atherosclerosis in the explanted hearts of patients undergoing heart transplantation. J Med Virol. 44:1994;305-309.
26. Zhou Y.F., Leon M.B., Waclawiw M.A., et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 335:1996;624-630.
27. Mendall M.A., Goggin P.M., Molineaux N., et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 71:1994;437-439.
28. Patel P., Mendall M.A., Carrington D., et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 311:1995;711-714.
29. Ludwig E., Corneli P.S., Anderson J.L., Marshall H.W., Lalouel J.-M., Ward R.H. Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation. 91:1995;2120-2124.
30. McClellan T., Jorde L.B., Skolnick M.H. Genetic distances between the Utah Mormons and related populations. Am J Hum Genet. 36:1984;836-857.
31. Liuzzo G., Biasucci L.M., Rebuzzi A.G., et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 94:1996;2373-2380.
32. Bernersen B., Johnsen R., Bostad L., Straume B., Sommer A.-I., Burhol P.G. Is Helicobacter pylori the cause of dyspepsia? BMJ. 304:1992;1276-1278.
33. Walsh J.H., Peterson W.L. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 333:1995;984-991.
34. Mattila K.J., Nieminen M.S., Valtonen V., et al. Association between dental health and acute myocardial infarction. BMJ. 298:1989;779-781.
35. Grayston J.T. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis. 15:1992;757-761.
36. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82:1993;513-520.
37. Beatty W.L., Morrison R.P., Byrne G.I. Persistent chlamydiae from cell culture to a paradigm for chlamydial pathogenesis . Microbiol Rev. 58:1994;686-699.
38. Knoebel E., Vijayagopal P., Figueroa J.E., Martin D.H. In vitro infection of smooth muscle cells by Chlamydia pneumoniae. Infect Immun. 65:1997;503-506.
39. Hendrix M.G.R., Daemen M., Bruggeman C.A. Cytomegalovirus nucleic acid distribution within the human vascular tree. Am J Pathol. 138:1991;563-567.
40. Gupta S., Leatham E.W., Carrington D., Mendall M.A., Kaski J.C., Camm A.J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404-407.
41. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
42. Muhlestein J.B., Anderson J.L., Hammond E.H., et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:1998;633-639.
43. Libby P., Egan D., Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. Circulation. 96:1997;4065-4103.